Actelion top pay no vote highlights time lag
This article was originally published in Scrip
That a company's board of directors may well be at odds with its shareholders, particularly when it comes to the pay packages of its executives and directors, has been illustrated at Actelion Pharmaceuticals' annual general meeting this week. 60.2% of votes cast opposed the Swiss firm's compensation report for last year, while only 38.6% endorsed it. However, the company insists that the vote reflects a historical reality and that it has already made changes to future plans that will meet with shareholder approval.